YDESW
YD Bio Limited Warrants
NASDAQ · Healthcare · Biotechnology · TW
$0.41
+8.58%Aug 31, 2026, 22:00 UTC
YD Bio Limited announced its unaudited financial results for the six months ended June 30, 2026.
Source:Jul 28, 2026, 12:00 UTC
YD Bio, YD Bio US, EG BioMed US, and Numia Health launched a six-month pilot collaboration to evaluate a cross-border clinical workflow for physician-ordered, blood-based cancer testing for patients in British Columbia, Canada.
Source:Jul 2, 2026, 12:00 UTC
YD Bio's affiliate EG BioMed US obtained out-of-state clinical laboratory licenses in Rhode Island and Pennsylvania, expanding its U.S. laboratory footprint to 46 states for DNA-methylation early cancer detection operations.
Source: